Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Report and Forecast 2025-2034
Description
The attention deficit hyperactivity disorder (ADHD) treatment market was valued at USD 14.64 Billion in 2024, driven by heightened awareness of ADHD among people across the 8 major markets. The market is expected to grow at a CAGR of 5.10% during the forecast period of 2025-2034, with values likely to reach USD 24.08 Billion by 2034.
Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Overview
Attention deficit hyperactivity disorder (ADHD) is a brain disorder which hampers the ability of a person to pay attention to things, along with behaviour control. It is among the most common brain disorders diagnosed in children. Both children and adults are affected by the condition, however, it is commonly diagnosed in children which further continues to adulthood.
Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Growth Drivers
Rising Incidence of the Disease
The increasing rates of ADHD diagnoses are highly contributing to the increased demand for ADHD treatment. However, the reason behind the heightening number of ADHD diagnoses is the increasing recognition of the condition. Parents are paying more attention to their children, therefore, the diagnosis rate of the condition is rising. As per the report published by the Centers for Disease Control and Prevention in May 2024, 1 in every 9 children in the United States between the age of 3-17 have been diagnosed with attention deficit hyperactivity disorder (ADHD).
Additionally, in 2022, a report by the American public broadcasting organization revealed that nearly 7.1 million people (including kids) were diagnosed with ADHD.
Additionally, the window of treatment for children suffering from ADHD is also wide open, as it was also found by the study that the total number of children taking medications was only half the number of children diagnosed with ADHD. This highlights a wide gap of unmet actions and initiatives to spread the awareness about the condition, propelling the possibilities of market expansion.
Adoption of Novel Therapeutics
As the healthcare domain is witnessing instrumental strides towards technological advancements, the ADHD treatment market is also influenced. The market players like Akili are coming to the forefront and establishing a new benchmark in the ADHD treatment market. Akili Interactive, a prescription-based digital medicine company announced the 510k clearance of its phone-based video game in June 2024. The game is curated and designed to manage attention-deficit hyperactivity disorder (ADHD). As the first-ever video game for ADHD management, it showcased notable efficacy of 83% clinical response in clinical trials. Such innovations have great potential in improving patient health as well as create huge market demand and support the upward trajectory of the market in the forecast period.
Surge in Drug Approvals to Meet Rising Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Demand
With increasing awareness, the diagnoses incidence is collectively booming. The market value is further fuelled by the escalating number of drug approvals for effective management of the disease. In May 2024, the US Food and Drug Administration (FDA) gave a nod to Tris Pharma’s Onyda XR (clonidine hydrochloride) indicated for the treatment of attention deficit hyperactivity disorder (ADHD). The drug is the first ever and only liquid stimulant ADHD medication receiving FDA approval in the United States. It is a once-a-day extended-release oral suspension with nighttime dosing indicated as a monotherapy for pediatric patients 6 years and older. Such drug approvals by the regulatory authorities are anticipated to propel market growth in the forecast period.
Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Trends
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Increasing Awareness of ADHD
There is a significant increase in the awareness about attention deficit hyperactivity disorder (ADHD) among people which is a major reason that people are coming forward to avail dedicated treatments.
Increasing Diagnosis Rates
The rising incidence of ADHD diagnosis can be attributed to heightened awareness. The application of new technologies to detect the condition at an early age is amongst the major market trends.
Improved Medication and Treatment
The market is experiencing a rise in research activities by institutions and healthcare facilities to interpret the condition better and analyse symptoms, helpful in developing improved medication and personalised treatment for patients.
Campaigns and Initiatives
The governments are taking several initiatives to increase the awareness of ADHD among people. It involves partnerships with non-profit organisations and academic institutions to launch campaigns and boost awareness about the condition. For instance, NHS England has proposed to launch a new attention deficit hyperactivity disorder (ADHD) taskforce in collaboration with the government to improve care for ADHD people.
Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Segmentation
The EMR’s report titled “Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Report and Forecast 2025-2034” offers a detailed analysis of the market based on the following segments:
Market Breakup by Treatment Type
Market Share by Treatment Type to Witness Substantial Growth
The market segmentation based on treatment type is broadly segmented into stimulants and non-stimulants. Stimulants are further divided into Amphetamine, Methylphenidate, Dextroamphetamine, Dexmethylphenidate and Lisdexamfetamine Dimesylate, whereas, non-stimulants include Atomoxetine, Bupropion, Guanfacine and Clonidine. The stimulants are expected to dominate the market segment as they are highly effective in managing ADHD among both children and adults. Stimulants are commonly preferred by medical professionals due to their proven efficacy in treating the condition and improving patient outcomes.
Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Analysis by Region
Based on region, the market report offers insights for the United States, EU-4 (Germany, France, Italy, Spain), the United Kingdom, Japan and India.
In the market segmentation based on region, the United States has the largest market share due to the rising incidence of the condition. The market share is also influenced by the heightened level of awareness among people about the ADHD condition. According to the data released by the U.S Centers for Disease Control and Prevention, 56.9% of children aged between 6-11 years, are currently receiving ADHD treatments.
Leading Players in the Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market
The key features of the market report comprise clinical trial analysis, grants analysis, funding and investment analysis and strategic initiatives by the leading players. The major companies in the market are as follows:
Takeda Pharmaceutical Company Limited
Headquartered in Tokyo, Japan, Takeda is a multinational pharmaceutical company. It is the third-largest pharmaceutical company in Asia. The company offers plasma-derived treatment therapies and vaccines focused on medical conditions such as oncology, rare diseases, neuroscience, and gastroenterology.
Aytu BioPharma, Inc.
Aytu BioPharma, Inc. headquartered in Denver, Colorado, is a dynamic speciality pharmaceutical company with an expanding portfolio of prescriptions primarily focused on complex conditions such as ADHD and other common conditions.
Eli Lilly and Company
Headquartered in Indiana, United States, Eli Lily and Company is a pharmaceutical company with an expanding foot reach in more than 125 countries. With primary drug offerings for conditions like diabetes, the company is also known for its clinical depression drugs like Prozac.
Pfizer Inc.
Headquartered in Manhattan, New York, Pfizer is a multinational pharmaceutical and biotechnology corporation. The company offers drugs and vaccines for the treatment of conditions such as immunology, oncology, cardiology, endocrinology, and neurology.
Other key players in the market include Noven Pharmaceuticals Inc. Supernus Pharmaceuticals, Inc., Johnson & Johnson Services Inc., Novartis AG, Curemark, LLC, Highland Therapeutics Inc., and GlaxoSmithKline Plc.
Key Questions Answered in the Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market
Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Overview
Attention deficit hyperactivity disorder (ADHD) is a brain disorder which hampers the ability of a person to pay attention to things, along with behaviour control. It is among the most common brain disorders diagnosed in children. Both children and adults are affected by the condition, however, it is commonly diagnosed in children which further continues to adulthood.
Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Growth Drivers
Rising Incidence of the Disease
The increasing rates of ADHD diagnoses are highly contributing to the increased demand for ADHD treatment. However, the reason behind the heightening number of ADHD diagnoses is the increasing recognition of the condition. Parents are paying more attention to their children, therefore, the diagnosis rate of the condition is rising. As per the report published by the Centers for Disease Control and Prevention in May 2024, 1 in every 9 children in the United States between the age of 3-17 have been diagnosed with attention deficit hyperactivity disorder (ADHD).
Additionally, in 2022, a report by the American public broadcasting organization revealed that nearly 7.1 million people (including kids) were diagnosed with ADHD.
Additionally, the window of treatment for children suffering from ADHD is also wide open, as it was also found by the study that the total number of children taking medications was only half the number of children diagnosed with ADHD. This highlights a wide gap of unmet actions and initiatives to spread the awareness about the condition, propelling the possibilities of market expansion.
Adoption of Novel Therapeutics
As the healthcare domain is witnessing instrumental strides towards technological advancements, the ADHD treatment market is also influenced. The market players like Akili are coming to the forefront and establishing a new benchmark in the ADHD treatment market. Akili Interactive, a prescription-based digital medicine company announced the 510k clearance of its phone-based video game in June 2024. The game is curated and designed to manage attention-deficit hyperactivity disorder (ADHD). As the first-ever video game for ADHD management, it showcased notable efficacy of 83% clinical response in clinical trials. Such innovations have great potential in improving patient health as well as create huge market demand and support the upward trajectory of the market in the forecast period.
Surge in Drug Approvals to Meet Rising Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Demand
With increasing awareness, the diagnoses incidence is collectively booming. The market value is further fuelled by the escalating number of drug approvals for effective management of the disease. In May 2024, the US Food and Drug Administration (FDA) gave a nod to Tris Pharma’s Onyda XR (clonidine hydrochloride) indicated for the treatment of attention deficit hyperactivity disorder (ADHD). The drug is the first ever and only liquid stimulant ADHD medication receiving FDA approval in the United States. It is a once-a-day extended-release oral suspension with nighttime dosing indicated as a monotherapy for pediatric patients 6 years and older. Such drug approvals by the regulatory authorities are anticipated to propel market growth in the forecast period.
Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Trends
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Increasing Awareness of ADHD
There is a significant increase in the awareness about attention deficit hyperactivity disorder (ADHD) among people which is a major reason that people are coming forward to avail dedicated treatments.
Increasing Diagnosis Rates
The rising incidence of ADHD diagnosis can be attributed to heightened awareness. The application of new technologies to detect the condition at an early age is amongst the major market trends.
Improved Medication and Treatment
The market is experiencing a rise in research activities by institutions and healthcare facilities to interpret the condition better and analyse symptoms, helpful in developing improved medication and personalised treatment for patients.
Campaigns and Initiatives
The governments are taking several initiatives to increase the awareness of ADHD among people. It involves partnerships with non-profit organisations and academic institutions to launch campaigns and boost awareness about the condition. For instance, NHS England has proposed to launch a new attention deficit hyperactivity disorder (ADHD) taskforce in collaboration with the government to improve care for ADHD people.
Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Segmentation
The EMR’s report titled “Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Report and Forecast 2025-2034” offers a detailed analysis of the market based on the following segments:
Market Breakup by Treatment Type
- Stimulants
- Amphetamine
- Methylphenidate
- Dextroamphetamine
- Dexmethylphenidate
- Lisdexamfetamine Dimesylate
- Non-Stimulants
- Atomoxetine
- Bupropion
- Guanfacine
- Clonidine
- Adult
- Children
- Male
- Female
- Hospital Pharmacies
- Retail Pharmacies
- Others
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
- India
Market Share by Treatment Type to Witness Substantial Growth
The market segmentation based on treatment type is broadly segmented into stimulants and non-stimulants. Stimulants are further divided into Amphetamine, Methylphenidate, Dextroamphetamine, Dexmethylphenidate and Lisdexamfetamine Dimesylate, whereas, non-stimulants include Atomoxetine, Bupropion, Guanfacine and Clonidine. The stimulants are expected to dominate the market segment as they are highly effective in managing ADHD among both children and adults. Stimulants are commonly preferred by medical professionals due to their proven efficacy in treating the condition and improving patient outcomes.
Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Analysis by Region
Based on region, the market report offers insights for the United States, EU-4 (Germany, France, Italy, Spain), the United Kingdom, Japan and India.
In the market segmentation based on region, the United States has the largest market share due to the rising incidence of the condition. The market share is also influenced by the heightened level of awareness among people about the ADHD condition. According to the data released by the U.S Centers for Disease Control and Prevention, 56.9% of children aged between 6-11 years, are currently receiving ADHD treatments.
Leading Players in the Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market
The key features of the market report comprise clinical trial analysis, grants analysis, funding and investment analysis and strategic initiatives by the leading players. The major companies in the market are as follows:
Takeda Pharmaceutical Company Limited
Headquartered in Tokyo, Japan, Takeda is a multinational pharmaceutical company. It is the third-largest pharmaceutical company in Asia. The company offers plasma-derived treatment therapies and vaccines focused on medical conditions such as oncology, rare diseases, neuroscience, and gastroenterology.
Aytu BioPharma, Inc.
Aytu BioPharma, Inc. headquartered in Denver, Colorado, is a dynamic speciality pharmaceutical company with an expanding portfolio of prescriptions primarily focused on complex conditions such as ADHD and other common conditions.
Eli Lilly and Company
Headquartered in Indiana, United States, Eli Lily and Company is a pharmaceutical company with an expanding foot reach in more than 125 countries. With primary drug offerings for conditions like diabetes, the company is also known for its clinical depression drugs like Prozac.
Pfizer Inc.
Headquartered in Manhattan, New York, Pfizer is a multinational pharmaceutical and biotechnology corporation. The company offers drugs and vaccines for the treatment of conditions such as immunology, oncology, cardiology, endocrinology, and neurology.
Other key players in the market include Noven Pharmaceuticals Inc. Supernus Pharmaceuticals, Inc., Johnson & Johnson Services Inc., Novartis AG, Curemark, LLC, Highland Therapeutics Inc., and GlaxoSmithKline Plc.
Key Questions Answered in the Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market
- What was the attention deficit hyperactivity disorder (ADHD) treatment market value in 2023?
- What is the attention deficit hyperactivity disorder (ADHD) treatment market forecast outlook for 2025-2034?
- What are the regional markets covered in the EMR report?
- What is market segmentation based on treatment type?
- What is the market breakup based on gender?
- What is the market breakup based on age group?
- Who are the major distribution channels in the market?
- What are the major factors aiding the attention deficit hyperactivity disorder (ADHD) treatment market demand?
- How has the market performed so far and how is it anticipated to perform in the coming years?
- What are the market's major drivers, opportunities, and restraints?
- Which regional market is expected to lead the market share in the forecast period?
- Which country is expected to experience expedited growth during the forecast period?
- What are the major attention deficit hyperactivity disorder (ADHD) treatment market trends?
- Which treatment type will dominate the market share?
- Which distribution channel is expected to have a high market value in the coming years?
- Which end-user is projected to contribute to the highest market growth?
- Who are the key players involved in the attention deficit hyperactivity disorder (ADHD) treatment market?
- What is the patent landscape of the market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers and acquisitions among the key market players shaping the market dynamics?
Table of Contents
400 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Overview – 8 Major Markets
- 3.1 Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Historical Value (2018-2024)
- 3.2 Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Forecast Value (2025-2034)
- 4 Vendor Positioning Analysis
- 4.1 Key Vendors
- 4.2 Prospective Leaders
- 4.3 Niche Leaders
- 4.4 Disruptors
- 5 Attention Deficit Hyperactivity Disorder (ADHD) Treatment Overview
- 5.1 Guidelines and Stages
- 5.2 Pathophysiology
- 5.3 Screening and Diagnosis
- 5.4 Treatment Pathway
- 6 Patient Profile
- 6.1 Patient Profile Overview
- 6.2 Patient Psychology and Emotional Impact Factors
- 6.3 Risk Assessment and Treatment Success Rate
- 7 Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market - Epidemiology Scenario and Forecast – 8 Major Markets
- 7.1 8MM Epidemiology Scenario Overview (2018-2034)
- 7.1.1 Prevalence, by Country
- 7.1.1.1 United States
- 7.1.1.2 United Kingdom
- 7.1.1.3 EU4
- 7.1.1.4 India
- 7.1.1.5 Japan
- 7.1.2 Diagnosed Cases, by Country
- 7.1.2.1 United States
- 7.1.2.2 United Kingdom
- 7.1.2.3 EU4
- 7.1.2.4 India
- 7.1.2.5 Japan
- 7.1.3 Treatment seeking rate, by Country
- 7.1.3.1 United States
- 7.1.3.2 United Kingdom
- 7.1.3.3 EU4
- 7.1.3.4 India
- 7.1.3.5 Japan
- 8 Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Landscape – 8 Major Markets
- 8.1 Attention Deficit Hyperactivity Disorder (ADHD) Treatment: Developers Landscape
- 8.1.1 Analysis by Year of Establishment
- 8.1.2 Analysis by Company Size
- 8.1.3 Analysis by Region
- 8.2 Attention Deficit Hyperactivity Disorder (ADHD) Treatment: Product Landscape
- 8.2.1 Analysis by Treatment Type
- 8.2.2 Analysis by Age Group
- 8.2.3 Analysis by Route of Administration
- 9 Attention Deficit Hyperactivity Disorder (ADHD) Treatment Challenges and Unmet Needs
- 9.1 Treatment Pathway Challenges
- 9.2 Compliance and Drop-Out Analysis
- 9.3 Awareness and Prevention Gaps
- 10 Cost of Treatment
- 11 Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Dynamics
- 11.1 Market Drivers and Constraints
- 11.2 SWOT Analysis
- 11.2.1 Strengths
- 11.2.2 Weaknesses
- 11.2.3 Opportunities
- 11.2.4 Threats
- 11.3 PESTEL Analysis
- 11.3.1 Political
- 11.3.2 Economic
- 11.3.3 Social
- 11.3.4 Technological
- 11.3.5 Legal
- 11.3.6 Environment
- 11.4 Porter’s Five Forces Model
- 11.4.1 Bargaining Power of Suppliers
- 11.4.2 Bargaining Power of Buyers
- 11.4.3 Threat of New Entrants
- 11.4.4 Threat of Substitutes
- 11.4.5 Degree of Rivalry
- 11.5 Key Demand Indicators
- 11.6 Key Price Indicators
- 11.7 Industry Events, Initiatives, and Trends
- 11.8 Value Chain Analysis
- 12 Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Segmentation (218-2034) - 8 Major Markets
- 12.1 Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market (2018-2034) by Treatment Type
- 12.1.1 Market Overview
- 12.1.2 Stimulants
- 12.1.2.1 Amphetamine
- 12.1.2.2 Methylphenidate
- 12.1.2.3 Dextroamphetamine
- 12.1.2.4 Dexmethylphenidate
- 12.1.2.5 Lisdexamfetamine Dimesylate
- 12.1.3 Non-Stimulants
- 12.1.3.1 Atomoxetine
- 12.1.3.2 Bupropion
- 12.1.3.3 Guanfacine
- 12.1.3.4 Clonidine
- 12.2 Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market (2018-2034) by Age Group
- 12.2.1 Market Overview
- 12.2.2 Adult
- 12.2.3 Children
- 12.3 Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market (2018-2034) by Gender
- 12.3.1 Market Overview
- 12.3.2 Male
- 12.3.3 Female
- 12.4 Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market (2018-2034) by Distribution Channel
- 12.4.1 Market Overview
- 12.4.2 Hospital Pharmacies
- 12.4.3 Retail Pharmacies
- 12.4.4 Others
- 12.5 Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market (2018-2034) by Region
- 12.5.1 Market Overview
- 12.5.2 United States
- 12.5.3 EU-4 and the United Kingdom
- 12.5.3.1 Germany
- 12.5.3.2 France
- 12.5.3.3 Italy
- 12.5.3.4 Spain
- 12.5.3.5 United Kingdom
- 12.5.4 Japan
- 12.5.5 India
- 13 United States Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market (218-2034)
- 13.1 United States Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Historical Value (2018-2024)
- 13.2 United States Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Forecast Value (2025-2034)
- 13.3 United States Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market (2018-2034) by Treatment T ype
- 13.3.1 Market Overview
- 13.3.2 Stimulants
- 13.3.2.1 Amphetamine
- 13.3.2.2 Methylphenidate
- 13.3.2.3 Dextroamphetamine
- 13.3.2.4 Dexmethylphenidate
- 13.3.2.5 Lisdexamfetamine Dimesylate
- 13.3.3 Non-Stimulants
- 13.3.3.1 Atomoxetine
- 13.3.3.2 Bupropion
- 13.3.3.3 Guanfacine
- 13.3.3.4 Clonidine
- 13.4 United States Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market (2018-2034) by Age Group
- 13.4.1 Market Overview
- 13.4.2 Adult
- 13.4.3 Children
- 13.5 United States Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market (2018-2034) by Gender
- 13.5.1 Market Overview
- 13.5.2 Male
- 13.5.3 Female
- 13.6 United States Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market (2018-2034) by Distribution Channel
- 13.6.1 Market Overview
- 13.6.2 Hospital Pharmacies
- 13.6.3 Retail Pharmacies
- 13.6.4 Others
- 14 EU-4 and United Kingdom Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market (218-2034)
- 14.1 EU-4 and United Kingdom Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Historical Value (2018-2024)
- 14.2 EU-4 and United Kingdom Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Forecast Value (2025-2034)
- 14.3 EU-4 and United Kingdom Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market (2018-2034) by Treatment Type
- 14.3.1 Market Overview
- 14.3.2 Stimulants
- 14.3.2.1 Amphetamine
- 14.3.2.2 Methylphenidate
- 14.3.2.3 Dextroamphetamine
- 14.3.2.4 Dexmethylphenidate
- 14.3.2.5 Lisdexamfetamine Dimesylate
- 14.3.3 Non- Stimulants
- 14.3.3.1 Atomoxetine
- 14.3.3.2 Bupropion
- 14.3.3.3 Guanfacine
- 14.3.3.4 Clonidine
- 14.4 EU-4 and United Kingdom Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market (2018-2034) by Age Group
- 14.4.1 Market Overview
- 14.4.2 Adult
- 14.4.3 Children
- 14.5 EU-4 and United Kingdom Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market (2018-2034) by Gender
- 14.5.1 Market Overview
- 14.5.2 Male
- 14.5.3 Female
- 14.6 EU-4 and United Kingdom ttention Deficit Hyperactivity Disorder (ADHD) Treatment Market (2018-2034) by Distribution Channel
- 14.6.1 Market Overview
- 14.6.2 Hospital Pharmacies
- 14.6.3 Retail Pharmacies
- 14.6.4 Others
- 15 Japan Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market
- 15.1 Japan Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Historical Value (2018-2024)
- 15.2 Japan Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Forecast Value (2025-2034)
- 15.3 Japan Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market (2018-2034) by Treatment T ype
- 15.3.1 Market Overview
- 15.3.2 Stimulants
- 15.3.2.1 Amphetamine
- 15.3.2.2 Methylphenidate
- 15.3.2.3 Dextroamphetamine
- 15.3.2.4 Dexmethylphenidate
- 15.3.2.5 Lisdexamfetamine Dimesylate
- 15.3.3 Non-Stimulants
- 15.3.3.1 Atomoxetine
- 15.3.3.2 Bupropion
- 15.3.3.3 Guanfacine
- 15.3.3.4 Clonidine
- 15.4 Japan Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market (2018-2034) by Age Group
- 15.4.1 Market Overview
- 15.4.2 Adult
- 15.4.3 Children
- 15.5 Japan Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market (2018-2034) by Gender
- 15.5.1 Market Overview
- 15.5.2 Male
- 15.5.3 Female
- 15.6 Japan Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market (2018-2034) by Distribution Channel
- 15.6.1 Market Overview
- 15.6.2 Hospital Pharmacies
- 15.6.3 Retail Pharmacies
- 15.6.4 Others
- 16 India Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market
- 16.1 India Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market (2018-2034) Historical Value (2018-2024)
- 16.2 India Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market (2018-2034) Forecast Value (2025-2034)
- 16.3 India Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market (2018-2034) by Treatment T ype
- 16.3.1 Market Overview
- 16.3.2 Stimulants
- 16.3.2.1 Amphetamine
- 16.3.2.2 Methylphenidate
- 16.3.2.3 Dextroamphetamine
- 16.3.2.4 Dexmethylphenidate
- 16.3.2.5 Lisdexamfetamine Dimesylate
- 16.3.3 Non-Stimulants
- 16.3.3.1 Atomoxetine
- 16.3.3.2 Bupropion
- 16.3.3.3 Guanfacine
- 16.3.3.4 Clonidine
- 16.4 India Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market (2018-2034) by Age Group
- 16.4.1 Market Overview
- 16.4.2 Adult
- 16.4.3 Children
- 16.5 India Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market (2018-2034) by Gender
- 16.5.1 Market Overview
- 16.5.2 Male
- 16.5.3 Female
- 16.6 India Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market (2018-2034) by Distribution Channel
- 16.6.1 Market Overview
- 16.6.2 Hospital Pharmacies
- 16.6.3 Retail Pharmacies
- 16.6.4 Others
- 17 Regulatory Framework
- 17.1 Regulatory Overview
- 17.1.1 US FDA
- 17.1.2 EU EMA
- 17.1.3 Japan PMDA
- 17.1.4 India CDSCO
- 17.1.5 Others
- 18 Clinical Trials Analysis
- 18.1 Analysis by Trial Registration Year
- 18.2 Analysis by Trial Status
- 18.3 Analysis by Trial Phase
- 18.4 Analysis by Therapeutic Area
- 18.5 Analysis by Geography
- 19 Grants Analysis
- 19.1 Analysis by Year
- 19.2 Analysis by Amount Awarded
- 19.3 Analysis by Issuing Authority
- 19.4 Analysis by Grant Application
- 19.5 Analysis by Funding Institute
- 19.6 Analysis by NIH Departments
- 19.7 Analysis by Recipient Organization
- 20 Funding and Investment Analysis
- 20.1 Analysis by Funding Instances
- 20.2 Analysis by Type of Funding
- 20.3 Analysis by Funding Amount
- 20.4 Analysis by Leading Players
- 20.5 Analysis by Leading Investors
- 20.6 Analysis by Geography
- 21 Strategic Initiatives
- 21.1 Analysis by Partnership Instances
- 21.2 Analysis by Type of Partnership
- 21.3 Analysis by Leading Players
- 21.4 Analysis by Geography
- 22 Supplier Landscape
- 22.1 Market Share by Top 5 Companies
- 22.2 Takeda Pharmaceutical Company Limited
- 22.2.1 Financial Analysis
- 22.2.2 Product Portfolio
- 22.2.3 Demographic Reach and Achievements
- 22.2.4 Company News and Development
- 22.2.5 Certifications
- 22.3 Aytu BioPharma, Inc.
- 22.3.1 Financial Analysis
- 22.3.2 Product Portfolio
- 22.3.3 Demographic Reach and Achievements
- 22.3.4 Company News and Development
- 22.3.5 Certifications
- 22.4 Eli Lilly and Company
- 22.4.1 Financial Analysis
- 22.4.2 Product Portfolio
- 22.4.3 Demographic Reach and Achievements
- 22.4.4 Company News and Development
- 22.4.5 Certifications
- 22.5 Pfizer Inc.
- 22.5.1 Financial Analysis
- 22.5.2 Product Portfolio
- 22.5.3 Demographic Reach and Achievements
- 22.5.4 Company News and Development
- 22.5.5 Certifications
- 22.6 Noven Pharmaceuticals Inc.
- 22.6.1 Financial Analysis
- 22.6.2 Product Portfolio
- 22.6.3 Demographic Reach and Achievements
- 22.6.4 Company News and Development
- 22.6.5 Certifications
- 22.7 Supernus Pharmaceuticals, Inc.
- 22.7.1 Financial Analysis
- 22.7.2 Product Portfolio
- 22.7.3 Demographic Reach and Achievements
- 22.7.4 Company News and Development
- 22.7.5 Certifications
- 22.8 Johnson & Johnson Servi ces Inc.
- 22.8.1 Financial Analysis
- 22.8.2 Product Portfolio
- 22.8.3 Demographic Reach and Achievements
- 22.8.4 Company News and Development
- 22.8.5 Certifications
- 22.9 Novartis A G
- 22.9.1 Financial Analysis
- 22.9.2 Product Portfolio
- 22.9.3 Demographic Reach and Achievements
- 22.9.4 Company News and Development
- 22.9.5 Certifications
- 22.10 Curemark, LLC
- 22.10.1 Financial Analysis
- 22.10.2 Product Portfolio
- 22.10.3 Demographic Reach and Achievements
- 22.10.4 Company News and Development
- 22.10.5 Certifications
- 22.11 GlaxoSmithKline Plc
- 22.11.1 Financial Analysis
- 22.11.2 Product Portfolio
- 22.11.3 Demographic Reach and Achievements
- 22.11.4 Company News and Development
- 22.11.5 Certifications
- 22.12 Highland Therapeutics Inc.
- 22.12.1 Financial Analysis
- 22.12.2 Product Portfolio
- 22.12.3 Demographic Reach and Achievements
- 22.12.4 Company News and Development
- 22.12.5 Certifications
- 23 Attention Deficit Hyperactivity Disorder (ADHD) Treatment Treatment Drugs - Distribution Model (Additional Insight)
- 23.1 Overview
- 23.2 Potential Distributors
- 23.3 Key Parameters for Distribution Partner Assessment
- 24 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 25 Payment Methods (Additional Insight)
- 25.1 Government Funded
- 25.2 Private Insurance
- 25.3 Out-of-Pocket
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
